Your browser doesn't support javascript.
loading
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
Agostinetto, E; Buisseret, L; Salgado, R; Kok, M; Ignatiadis, M.
Affiliation
  • Agostinetto E; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
  • Buisseret L; Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
  • Salgado R; Department of Pathology, ZAS Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum cancer Centre, Melbourne, Belgium.
  • Kok M; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ignatiadis M; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium. Electronic address: michail.ignatiadis@hubruxelles.be.
Ann Oncol ; 35(5): 409-411, 2024 May.
Article in En | MEDLINE | ID: mdl-38484973
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neoplasm, Residual / Neoadjuvant Therapy / Triple Negative Breast Neoplasms Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: Belgium
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neoplasm, Residual / Neoadjuvant Therapy / Triple Negative Breast Neoplasms Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: Belgium